Regan J. Lauer - Dec 15, 2024 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role: Chief Accounting Officer
Signature: /s/ Jason Liljestrom, as Attorney-in-Fact
Stock symbol: IBRX
Transactions as of: Dec 15, 2024
Transactions value $: -$21,534
Form type: 4
Date filed: 12/16/2024, 07:36 PM
Previous filing: Feb 26, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IBRX	Common Stock	Options Exercise	$0	+21K	+22.29%	$0.00	115K	Dec 15, 2024	Direct
transaction	IBRX	Common Stock	Tax liability	-$21.5K	-7.5K	-6.5%	$2.87	108K	Dec 15, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IBRX	Restricted Stock Units	Options Exercise	$0	-21K	-100%	$0.00	0	Dec 15, 2024	Common Stock	21K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 15, 2024, the Reporting Person's restricted stock units ("RSUs") vested. The closing price of Immunity Bio, Inc.'s common stock on December 13, 2024 was the settlement price used to calculate the shares withheld.
F2	Each RSU represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F3	Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the RSUs vested as follows: 1/3rd of the RSUs subject to the award vested June 15, 2023, 1/3rd of the RSUs subject to the award vested December 15, 2023, and 1/3rd of the RSUs subject to the award vested December 15, 2024 such that the award was fully vested on December 15, 2024.